NephroNet

NephroNet

Share

06/18/2026

🧬 New Hope for IgA Nephropathy Patients!
The phase 2 ENVISION trial shows that sibeprenlimab, an APRIL-targeting monoclonal antibody, significantly reduced proteinuria in high-risk patients with IgA nephropathy who had already received standard care.
πŸ“‰ At 12 months:
βœ”οΈ Up to 62% reduction in proteinuria with sibeprenlimab
βœ”οΈ Slower decline in kidney function (eGFR) compared to placebo
βœ”οΈ Similar safety profile between treatment and placebo groups
These results suggest sibeprenlimab may offer a novel, effective therapy for IgA nephropathy. πŸ’‘
πŸ”— Learn more: https://ow.ly/cwTv50WMnJr

Healthy Eating for Adults with Chronic Kidney Disease - NIDDK 06/12/2026

Healthy Eating for Adults with Chronic Kidney Disease

Healthy Eating for Adults with Chronic Kidney Disease - NIDDK Advice about what to eat and drink to slow chronic kidney disease (CKD), including suggestions to work with a dietitian to create and adjust meal plans.

06/01/2026

πŸ©ΊπŸ’‘ Nephrology Insight of the Week

πŸ” Kidney health is more than numbers β€” it’s about understanding the interplay between heart, immune system, and renal function. From IgA nephropathy research uncovering new treatment targets, to innovative trials using advanced diagnostics like mNGS for faster infection detection, the future of kidney care is precision-driven.

πŸ’¬ Why it matters:
Early detection, targeted therapies, and individualized treatment plans mean better outcomes for patients with complex kidney diseases.
βœ… Stay informed.
βœ… Support research.
βœ… Advocate for kidney health.

05/28/2026

πŸ§ πŸ’Š Ticagrelor vs. Clopidogrel in Stroke Patients with CYP2C19 LOF β€” Age & Kidney Function Matter

Objective:
Compare efficacy and safety of ticagrelor-aspirin vs. clopidogrel-aspirin in CYP2C19 loss-of-
function carriers with stroke, stratified by age and renal function.

Study details:
Data from CHANCE-2 trial.
Primary endpoint: new stroke within 90 days.
Safety endpoint: bleeding events.
Stratification by age (90 mL/min/1.73 mΒ²
Mild impairment: eGFR 60–89
Moderate/severe impairment: eGFR 90):
Ticagrelor significantly reduced stroke risk in both β‰₯65 years (HR 0.53, p = 0.008) and

05/25/2026

United in remembrance. Stronger together.

Want your business to be the top-listed Advertising & Marketing Company in Lawrenceville?
Click here to claim your Sponsored Listing.

Telephone

Address

Lawrenceville, GA

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm